Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed
Planned sales, announced before they happen

4 trading plans running, 56 Form 144 notices for $557.0M

10-Q, 10-K and Form 144
Plans running now 4 Frank Torti,, Eric Venker, Meghan FitzGerald, Melissa Epperly
Plans adopted 7 reported since Jun 28, 2023 Form 144 notices 56 $557.0M the sellers expected to sell

What ROIV's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Jun 25, 2024 to Oct 20, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Frank Torti,
President and Vant Chair
Adopted 10b5-1 plan Aug 13, 2026 10-Q Nov 9, 2026
What the company wrote
On August 13, 2026, Dr. Frank Torti, President and Vant Chair of our subsidiary Roivant Sciences, Inc., entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 5,583,448 common shares held by Dr. Torti between November 12, 2026 and June 20, 2027.
Eric Venker
President and Immunovant CEO
Adopted 10b5-1 plan Jun 30, 2026 10-Q Aug 6, 2026
What the company wrote
On June 30, 2026, Eric Venker, President and Immunovant CEO of our subsidiary Roivant Sciences, Inc., entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 1,787,943 common shares held by Dr. Venker between October 20, 2026 and October 20, 2027.
Meghan FitzGerald
director
Adopted 10b5-1 plan Mar 30, 2026 10-K May 20, 2026
What the company wrote
On March 30, 2026, Meghan FitzGerald, a director of RSL, entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale between July 29, 2026 and July 1, 2027 of up to 30,000 common shares held by Ms. FitzGerald as well as up to 40% of the net number of common shares resulting from the RSU vesting event on September 10, 2026.
Melissa Epperly
director
Adopted 10b5-1 plan Mar 30, 2026 10-K May 20, 2026
What the company wrote
On March 30, 2026, Melissa Epperly, a director of RSL, entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale between July 29, 2026 and June 30, 2027 of up to 71,000 common shares held by Ms. Epperly as well as up to 40% of the net number of common shares resulting from the RSU vesting event on September 10, 2026.
Frank Torti
President and Vant Chair
Adopted 10b5-1 plan Nov 20, 2025 10-Q Feb 6, 2026
What the company wrote
On November 20, 2025, Frank Torti, President and Vant Chair of our subsidiary Roivant Sciences, Inc. entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 3,000,000 common shares held by Dr. Torti between February 19, 2026 and June 30, 2026
Eric Venker
President and Chief Operating Officer
Adopted 10b5-1 plan Mar 28, 2025 10-K May 29, 2025
Eric Venker
President, Chief Operating Officer
Adopted 10b5-1 plan Jun 25, 2024 10-Q Aug 9, 2024

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Jun 28, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 13, 2026 RICHARD PULIK
Officer
125,000 $5.2M
Nov 13, 2026 Pulik Richard
Officer
175,000 $7.3M
Nov 12, 2026 RICHARD PULIK
Officer, Director
175,000 $7.3M
Nov 10, 2026 Venker Eric
Officer
187,943 $7.6M
Nov 10, 2026 FRANK M TORTI
Officer
1,234,964 $50.7M
Nov 10, 2026 MATTHEW ADAM GLINE
Officer, Director
164,136 $6.7M
Nov 10, 2026 MAYUKH SUKHATME
Officer, Director
173,725 $7.1M
Nov 10, 2026 MAYUKH SUKHATME
Officer, Director
173,725 $7.1M
Nov 10, 2026 MATTHEW ADAM GLINE
Officer, Director
164,136 $6.7M
Nov 10, 2026 FRANK M TORTI
Officer
1,234,964 $50.7M
Nov 10, 2026 RICHARD PULIK
Officer, Director
125,000 $5.2M
Nov 3, 2026 Venker Eric
Officer
200,000 $7.3M
Oct 28, 2026 Venker Eric
Officer
200,000 $7.3M
Oct 20, 2026 Venker Eric
Officer
200,000 $7.0M
Sep 30, 2026 Venker Eric
Officer
200,000 $7.3M
Sep 15, 2026 MELISSA EPPERLY
Director
22,688 $931K
Sep 15, 2026 MEGHAN FITZGERALD
Officer
5,112 $210K
Sep 8, 2026 MEGHAN FITZGERALD
Director
20,000 $699K
Aug 28, 2026 Venker Eric
Officer
200,000 $7.1M
Aug 21, 2026 MAYUKH SUKHATME
Officer, Director
144,756 $5.3M
Aug 20, 2026 MAYUKH SUKHATME
Officer, Director
17,519 $653K
Aug 19, 2026 MAYUKH SUKHATME
Officer, Director
172,899 $6.4M
Aug 18, 2026 MAYUKH SUKHATME
Officer, Director
136,942 $5.0M
Aug 17, 2026 MAYUKH SUKHATME
Officer, Director
284,707 $10.3M
Aug 14, 2026 MAYUKH SUKHATME
Officer, Director
243,177 $8.8M
Jul 27, 2026 Venker Eric
Officer
200,000 $7.0M
Jun 30, 2026 MEGHAN FITZGERALD
Director
10,000 $347K
Jun 30, 2026 KEITH S MANCHESTER
Director
200,000 $7.1M
Jun 29, 2026 MELISSA EPPERLY
Director
17,750 $605K
Jun 26, 2026 MAYUKH SUKHATME
Officer, Director
500,000 $17.0M
Jun 25, 2026 MAYUKH SUKHATME
Officer, Director
500,000 $17.1M
Jun 24, 2026 Venker Eric
Officer
200,000 $6.6M
May 22, 2026 Venker Eric
Officer
200,000 $6.1M
Apr 20, 2026 Venker Eric
Officer
200,000 $5.9M
Apr 16, 2026 Gline Matthew
Officer
289,774 $8.4M
Apr 16, 2026 Gline Matthew
Officer
289,774 $8.4M
Apr 8, 2026 JENNIFER HUMES
Officer
13,538 $384K
Mar 26, 2026 MEGHAN FITZGERALD
Director
70,000 $1.9M
Mar 17, 2026 Venker Eric
Officer
200,000 $5.6M
Mar 16, 2026 MELISSA B EPPERLY
Director
41,861 $1.2M
Feb 20, 2026 FRANK TORTI
Officer
1,600,000 $44.0M
Feb 19, 2026 FRANK TORTI
Officer
1,400,000 $38.5M
Feb 13, 2026 Venker Eric
Officer
200,000 $5.3M
Feb 9, 2026 Sukhatme Mayukh
Officer
339,441 $9.0M
Jan 12, 2026 Venker Eric
Officer
200,000 $4.4M
Dec 31, 2025 Sukhatme Mayukh
Officer
1,018,995 $22.1M
Dec 29, 2025 Sukhatme Mayukh
Officer
311,873 $6.8M
Dec 29, 2025 ERIC VENKER
Officer
75,000 $1.7M
Dec 29, 2025 FRANK M TORTI
Officer, Director
64,891 $1.5M
Dec 23, 2025 RICHARD PULIK
Officer
260,000 $5.8M
Dec 23, 2025 RICHARD PULIK TRUST
Officer
146,731 $3.3M
Dec 23, 2025 ERIC VENKER
Officer
200,000 $4.5M
Dec 17, 2025 Sukhatme Mayukh
Officer
26,831 $619K
Dec 15, 2025 Gline Matthew
Officer
1,740,000 $37.7M
Dec 15, 2025 Gline Matthew
Officer
1,740,000 $37.7M
Dec 9, 2025 Venker Eric
Officer
200,000 $4.2M
Show the other 48 notices

From the Form 144 XML filed with the SEC, since Dec 9, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.